Aravive Inc

Aravive — Investor Presentation (January 2022)

46 slides from Aravive's investor presentation, Jan 4, 2022

  1. Slide 1: Developing Transformative Targeted Cancer Therapeutics

    ¢°9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation January 2022 ‘ARAV (NASDAQ)

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements ‘This presentation contains forward-looking statements that may discuss Aravve's plans, goals, intentions and expectations as to future trends, events, resuts of ‘operations, financial condition or other matters. Forward-looking statements generally include statements that

  3. Slide 3: Developing Transformative Targeted Cancer Therapeutics

    Developing Transformative Targeted Cancer Therapeutics Batiraxcept (AVB-500): Differentiated Approach to Targeted Inhibition of GAS6/AXL Signaling Pathway Multiple Upcoming Clinical Milestones Registrational Phase 3 Trial in Platinum-Resistant Ovarian Cancer (PROC) Ongoing Phase 1b trial demonstrate

  4. Slide 4: Experienced Management and Board of Directors

    Experienced Management and Board of Directors SENIOR MANAGEMENT af £ ceo ‘oMo cro GollMetnyre, PhO.,ORBT Reshma Rangwale, M.D. Pho. Vinay Shah BOARD OF DIRECTORS LAER Chatman ofthe Bost Dect Director rector vector vector vector rector Freatsaian,” Anatoni,Ph0. Pour, Jn cinta, sight, Mchonoges eng Ph

  5. Slide 5: Aravive Pipeline

    Aravive Pipeline Opportunity for Expansion into Additional Indications and Drug Combinations Indication Preclinical Phase 1 Phase 2 Phase 3 Batiraxcept(AVB-500) OVARIAN CANCER Platnum Resistant Fast-Track Designation in U.S., Orphan Designation in EU (batraxcept + pactaxel) CLEAR CELL RENAL CANCER +

  6. Slide 6: Urgent Unmet Needs & Large Market Opportunities

    Urgent Unmet Needs & Large Market Opportunities ~106K Addressable Patients & Potential to Expand into Other Cancers and Earlier Lines of Therapy ®@ PROC Sth leading cause of cancer deaths among women in U.S. ~70% of patients diagnosed with advanced-stage disease ADDRESSABLE PATIENTS us. ~12,000 EU ~

  7. Slide 7: Upcoming Key Milestones

    Upcoming Key Milestones First Patient Dosedin Phase 2 in ccRCC Trial Completion of Enrolimentin Phase 1b Pancreatic ‘Adenocarcinoma Trial Initiation of Phase 2 Preliminary Phase 1b Pancreatic Adenocarcinoma Trial Pancreatic Adenocarcinoma Trial Data — Updated Phase 1b & Preliminary Phase Updated Pha

  8. Slide 8: GAS6/AXL Signaling Pathway

    GAS6/AXL Signaling Pathway Drives Activation, Migration and Invasion of Abnormal Cells Inhibiting GAS6 Preclinically ‘+ Anti-tumor activity in many tumor models, including ovarian, kidney, pancreatic, and breast + Blocks tumor invasion & metastasis + Overcomes acquired drug resistance + Ameliorates

  9. Slide 9: Modified AXL-Fc fusion protein

    Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 + ~200 fold greater affinity for human GAS6 compared to native AXL receptor + Preclinical data demonstrated relationship between affinity and anti-tumor activity + Good safety and PK profile + Structure mo

  10. Slide 10: Batiraxcept (AVB-500) Inhibits Metastasis and Tumor Growth

    Batiraxcept (AVB-500) Inhibits Metastasis and Tumor Growth Batiraxcept binds GAS6, preventing it GAS6 is the sole activating ligand of AXL oer Binding and aeiv sting ANC (©2021 Nabe, be © 0

  11. Slide 11: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)

    @ Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)

  12. Slide 12: Platinum-Resistant Ovarian Cancer Current Treatment Landscape

    Platinum-Resistant Ovarian Cancer Current Treatment Landscape Per current NCCN Clinical Practice Guidelines Clinical activity of paclitaxel in PROC! in Oncology, Version 1.2020, for Ovarian Cancer + 13-22% ORR (NCCN, 2020): + 28-4.4months PFS + For platinum-resistant disease, non-platinum-based + 10

  13. Slide 13: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies

    Summary of Phase 1a Healthy Volunteer and 1b PROC Studies Phase 1a single ascending dose and repeat dose study in healthy volunteers + 43 subjects participated; 42 dosed + Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs No anti-drug antibodies (ADA) + 10 mg/kg (IV) adm

  14. Slide 14: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure

    Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure Modeling Identified RP2D of 15 mg/kg + Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept due to its benign safety profile (Seay Poteet eel) A) and 15 mg/kg of Batiraxcept & Paclitaxel + Expos

  15. Slide 15: Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups

    Batiraxcept + Paclitaxel Clinical Activity in Bevacizumab Subgroups + Clinical activity higher in patients who had not received bevacizumab prior to entering study = Phenomenon observed in other studies* ~ Preclinical study showed bevacizumab treatment results in lower distribution of subsequent ant

  16. Slide 16: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients

    Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3+ Line of Therapy; Literature Demonstrates 85% of Patients on their 3° Line of Therapy have Progressive Disease by their First CT Scan’ PPS Monts for Per-Protoco! 10 mg/kg and 15 mg/kg

  17. Slide 17: Promising Responses in Patients in Later Lines of Therapy

    Promising Responses in Patients in Later Lines of Therapy and <3 Month Platinum-Free Interval Compared to Literature CLINICAL RESPONSE CLINICAL RESPONSE OFBATIRAXCEPT+ — “ OF CHEMOTHERAPY CHEMO'IN PATIENTS som IN PATIENTSWITH 0% WITH <3MO 50% | <3MO PLATINUM a PLATINUM FREE aoe FREE INTERVAL” 4% INT

  18. Slide 18: Potentially More Favorable Benefit/Risk Profile

    Potentially More Favorable Benefit/Risk Profile Compelling Anti-tumor Activity + ORR of 50% with 2 CRs, mPFS of 7.5 months, and mOS of 19 months in 10 & 15 mg/kg batiraxcept + PAC patients when trough levels exceeded MEC. + ORR of 37% in 10 and 15 mg/kg batiraxcept + PAC patients, regardless of whet

  19. Slide 19: Batiraxcept Phase 3 Adaptive Registration Trial Design in PROC

    Batiraxcept Phase 3 Adaptive Registration Trial Design in PROC (ClinicalTrials.gov NCT04729608) + FDA Feedback: If data positive, trial would support full approval in PROC; no further preclinical or clinical studies required for BLA at this time + Dosing: Batiraxcept every 2 weeks plus paclitaxel fo

  20. Slide 20: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)

    Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)

  21. Slide 21: ccRCC Current Treatment Landscape

    ccRCC Current Treatment Landscape Limited treatment options for patients who have failed 1L Cabozantinib is the predominant drug used in 2L+ ceRCC! Clinical Activity: ~ Confirmed objective response rate for (60mg) cabozantinib alone ranges from 17%-28% — PFS for (60mg) cabozantinib ranges from 7.4-9

  22. Slide 22: Strong Biological Rationale for Batiraxcept in ccRCC

    Strong Biological Rationale for Batiraxcept in ccRCC a e GAS6IAXL in ccRCC! 1% “ear “ * AXL plays significant role in ccRCC invasion & metastasis a + AXL highly expressed in aggressive ccRCC tumors and i associated with poor outcome fo + GASGIAXL signaling pathway is established therapeutic » target

  23. Slide 23: Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC

    Batiraxcept Effectively Targets Metastasis Preclinically in ccRCC Direct regulation of GAS6/AXL signaling by HIF Promotes Renal Metastasis through SRC and MET + Stress conditions in cell activate GAS6/AXL signaling to allow cell to survive + Hypoxia (stress factor), typical in solid tumors, induces

  24. Slide 24: Batiraxcept + Cabozantinib Phase 1b Trial Design in ccRCC

    Batiraxcept + Cabozantinib Phase 1b Trial Design in ccRCC Phase 1b Trial of Batiraxcept in Combination with Cabozantinib Batiraxcept+ Population: Timing: Cabozantinib + 26 patients + Completed enrollment in (N=26) + Histologically confirmed November 2021 BatiraxceptDose Levels: metastatic ccRCC and

  25. Slide 25: Safety Profile of Batiraxcept and Cabozantinib

    Safety Profile of Batiraxcept and Cabozantinib Safety Profile Consistent with the Established Safety Profile for Cabozantinib 15 mg/kg Batiraxcept + | 20 mg/kg Batiraxcept + Cabozantinib =16 Treatment Related Deaths 0 0 Grade 3 Adverse Events (AEs), related to 2 (12.5%): HTN, : 5 Batiraxcept and Cab

  26. Slide 26: Positive Initial Anti-Tumor Activity from Phase 1b Trial in ccRCC

    Positive Initial Anti-Tumor Activity from Phase 1b Trial in ccRCC 39% (9/23) Best Objective Response Rate; No Patients Progressed at 1st Scan 15 mg/kg Total Batiraxcept + Cabozantinib | _Cabozantinib 20 mg/kg Efficacy Evaluable Best Objective Response Rate (Confirmed + Unconfirmed)" Wee Hei DIR Part

  27. Slide 27: Depth and Duration of Response in ccRCC

    Depth and Duration of Response in ccRCC Batiraxcept + Cabozantinib + 20/23 (87%) demonstrated decrease intarget tumor size from baseline, some with deepening of response overtime; early tumor shrinkage is — a associated with overall survival (see Appendix) + 2123 (9%) progressed.at week 16 (107-008;

  28. Slide 28: Patient 105-006 Baseline and Week 8 Scans

    Baseline Week 8 Patient 105-006 had 4 target lesions at baseline measuring 25.6 cm in total. The images above depict two of these lesions (red arrows). The images on the left were obtained at baseline. The images on the right were obtained at Week 8. At week 8, 3 of the 4 target lesions, measuring a

  29. Slide 29: Phase 1b/2 Trial Designed to Accelerate Development in ccRCC

    Phase 1b/2 Trial Designed to Accelerate Development in ccRCC Strong Rationale to Evaluate Batiraxcept Monotherapy and Combination with Nivolumab + Cabozantinib in 1L Phase tband Bhace Sparta Phase 1b, N=16 Phase 2 Expansion, N=25 Batiraxcept ———————— 2L+ coRce: 15mgik mare batiraxcept+ cabozantinib

  30. Slide 30: Batiraxcept: Pancreatic Adenocarcinoma

    Batiraxcept: Pancreatic Adenocarcinoma

  31. Slide 31: Pancreatic Adenocarcinoma Current Treatment Landscape

    Pancreatic Adenocarcinoma Current Treatment Landscape Nap-Pacitaxe! Adverse Event(AE) SCemeitabine Gemcitabine + nab-paclitaxel used in 1L ea tweet treatment for advanced pancreatic Grades Henstaiogiene no raTnE “ adenocarcinoma Nevtropens 1501405 68%) “Leukoperia — 124408(915) Clinical Activity*: “

  32. Slide 32: Batiraxcept + gemcitabine + nab-paclitaxel Phase 1b/2 Trial Design

    Batiraxcept + gemcitabine + nab-paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma Ongoing Phase 1b Trial Phase 1b Population: Timing: + Patients (N~20) with advanced or + First patient dosed in Phase metastatic pancreatic 1b portion of trial in August Batiraxcept adenocarcinoma elig

  33. Slide 33: Initial Safety and Anti-Tumor Activity from Phase 1b Pancreatic Trial

    Initial Safety and Anti-Tumor Activity from Phase 1b Pancreatic Trial SAFE: + No unexpected safety signals observed in the first 6 patients who completed Cycle 1 + One grade 3 neutrophil count decreased related to the triplet; resolved within 7 days; no grade 4 or 5 events related to batiraxcept + S

  34. Slide 34: Corporate Highlights

    Corporate Highlights

  35. Slide 35: Financial Summary

    Financial Summary $67.5 Million* 20.9 Mii No Debt Cash and Cash Shares Equivalents Outstanding ata a f 3130202": oes icuce De 1 investmenttom Eshlnan Veokes, LCi Janay, 2022 ‘tncodes stouinesinenttomEshlman erhaes Leia 2022 ©2021 Arnie Ie (s) Cash Runway Expected to Fund Base Operating Plan into Q4

  36. Slide 36: Upcoming Key Milestones

    Upcoming Key Milestones First Patient Dosedin Phase 2 in ccRCC Trial Completion of Enrolimentin Phase 1b Pancreatic ‘Adenocarcinoma Trial Initiation of Phase 2 Preliminary Phase 1b Pancreatic Adenocarcinoma Trial Pancreatic Adenocarcinoma Trial Data — Updated Phase 1b & Preliminary Phase Updated Pha

  37. Slide 37: Developing Transformative Targeted Cancer Therapeutics

    Developing Transformative Targeted Cancer Therapeutics Batiraxcept (AVB-500): Differentiated Approach to Targeted Inhibition of GAS6/AXL Signaling Pathway Multiple Upcoming Clinical Milestones Registrational Phase 3 Trial in Platinum-Resistant Ovarian Cancer (PROC) Ongoing Phase 1b trial demonstrate

  38. Slide 38: Appendix

  39. Slide 39: GAS6/AXL Role in Cancer

    GAS6/AXL Role in Cancer Strong Biology, Challenging Target bisrcommeed Rankin etal, 2010 + Technology discovered by Aravive's scientific founder at Stanford Ovarian” 50.90% + Increased GAS6/AXL expression and signaling seen in ‘Sun etal, 2006 many cancers and correlated with a poor prognosis ‘Gustaf

  40. Slide 40: Strong Biological Rationale for Batiraxcept in PROC

    Strong Biological Rationale for Batiraxcept in PROC OVCAR (Ovarian Cancer Model)? + AXL expressed in 0% (0 of 10) of normal ovarian tissue’ + AXL expressed in 73% (219 of 297) of all ovarian tumor samples, demonstrating that AXL expression is significantly higher (P < 0.0001) in ‘ovarian carcinomas

  41. Slide 41: Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma

    Strong Biological Rationale for Batiraxcept in Pancreatic Adenocarcinoma + Preclinical data demonstrated increased + Studies have reported AXL expression survival in combination with gemcitabine, correlates with worse outcome in clinical decreased fibrosis, and decreased tumor samples from pancreati

  42. Slide 42: Strong Patent Protection

    Strong Patent Protection Stanford Licensed IP 4 Patent Family — Expiration 2034 us. 3 Issued Patents Worldwide: 10 Issued (2 HK Recorded) Patents (EP Validated In 18 EP Countries) 3 Pending Patent Applications, Stanford-Batiraxcept Co-owned IP 3 Patent Families — Expirations 2032 / 2033 / 2035 us. 3

  43. Slide 43: Clinical Activity of Cabozantinib in 2L+ ccRCC

    Clinical Activity of Cabozantinib in 2L+ ccRCC CANTATA NCT03634540 METEOR | CABOZANTINIB OZANTINIB + Belzutifan | CABOZANTINIB? 52) (N=330) Clinical Activity Objective Response % (95% Cl) 27.8 28.8(17.1-43.1) 17 (13-22) ‘Complete Response (%) 1 0 ) Stable Disease (%) 60 Not Reported 62 Progressive D

  44. Slide 44: Rates and Depth of Response Associated with Overall Survival in ccRCC

    Rates and Depth of Response Associated with Overall Survival in ccRCC + Retrospective studies have shown that early tumor shrinkage (eTS) based on target lesion reduction from baseline to first post-baseline scan, has predictive value for targeted therapies in RCC (Grunwald 2015; Grunwald 2016) + In

  45. Slide 45: Strategic Collaborations

    Strategic Collaborations 35DMedc Exclusive license agreement for development & commercialization of batiraxcept across all ‘oncology indications in Greater China + $12M upfront payment received + $207M total potential development and commercial milestone payments; SOM development milestones achieved

  46. Slide 46: Aravive: Developing Transformative Targeted Cancer Therapeutics

    ¢°9 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation January 2022 ‘ARAV (NASDAQ)

Aravive — Investor Presentation (January 2022) on 6ix